Why Ophthotech Corp. Shares Skyrocketed – Motley Fool

Why Ophthotech Corp. Shares Skyrocketed
Motley Fool
So what: Under the terms of the deal Ophthotech will retain all rights to Fovista within the United States with Novartis licensing the rights to the wet age-related macular degeneration drug hopeful in all other countries. The deal itself could be

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment